Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DOTAGA-FAP-2286-ALB
- Development stage
- Unknown
- Lead developer
- Kyoto University
01
Overview
DOTAGA-FAP-2286-ALB: sourced facts only. name: "In the cell competition binding study, In-DOTAGA-FAP-2286-ALB exhibited a higher FAP-binding affinity than In-DOTAGA-FAP-2286." [PMID:40236533]; target: "In the cell competition binding study, In-DOTAGA-FAP-2286-ALB exhibited a higher FAP-binding affinity than In-DOTAGA-FAP-2286." [PMID:40236533]; developer: "Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-Ku, Kyoto 606-8501, Japan." [PMID:40236533]
Beyond the preview
Go deeper on DOTAGA-FAP-2286-ALB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DOTAGA-FAP-2286-ALB.